Retatrutide vs Tirzepatide (Mounjaro): Results, Mechanisms and Side Effects

Sources: TRIUMPH-1 primary record, SURMOUNT-1 primary record, TRIUMPH-5 registry, TGA Mounjaro assessment, TGA weight-management registration, Lilly retatrutide information.

GIP and GLP-1 are nutrient-responsive hormones. Medicines acting at their receptors engage pathways involved in glucose regulation and body-weight control. Retatrutide adds glucagon-receptor activity to the two targets shared with tirzepatide.

Why add that target? The original retatrutide paper describes the premise that glucagon activity could enhance the effects of GIP/GLP-1 activity through reduced energy intake, increased energy expenditure, or both. In plain English, the research question concerns both how much energy comes in and how much is used. Jastreboff et al., 2023, introduction and discussion.

That is a biological rationale for testing the molecule. The human trial did not isolate each receptor's contribution, so it cannot tell us precisely how much of the observed weight loss came from glucagon activity or prove that everyone burns more calories. Clinical outcomes must establish the benefit of the complete compound.

Think of “triple agonist” as a description of what the molecule activates. It is not a rating out of three. More receptor targets do not automatically mean better results, fewer side effects or an appropriate choice for a particular person.

The compounds also cannot be compared milligram for milligram. A milligram describes mass. It does not standardise receptor activity, exposure or the clinical effect of different molecules. A 12 mg research group and a 15 mg research group are not evidence that one is weaker because the number is smaller.

Likewise, retatrutide is not tirzepatide with a separate glucagon product added. Trial results apply to the exact investigated molecule and formulation. They provide no basis for constructing a substitute combination from other products. Retatrutide phase 2 paper, SURMOUNT-1.

The table below uses the treatment-regimen analysis for both major trials. This approach estimates effects in the randomised population regardless of treatment discontinuation, rather than restricting the question to remaining on treatment. Each trial still used its own methods for handling missing data and other events.

Sources: TRIUMPH-1 abstract and analysis definition, SURMOUNT-1 abstract and analysis definition. These are separate placebo-controlled studies, not a retatrutide–tirzepatide trial. The target groups describe research methods, not a treatment schedule.

The difference between −25.0% and −20.9% is 4.1 percentage points. That arithmetic is correct, but calling it a 4.1-point treatment advantage would be incorrect: the drugs were not randomised against each other in these studies. Even subtracting each study's placebo change does not remove every difference between populations and trial procedures.

An average is also not a promise. It combines people with different responses. It does not tell a reader how much they would lose, whether that change would be tolerable or how long it would persist.

These figures need an analysis label. Lilly reported up to 28.3% weight reduction in TRIUMPH-1 and up to 22.5% in SURMOUNT-1 using the efficacy estimand, which addresses a different treatment question from the treatment-regimen analysis above. TRIUMPH-1 sponsor results, SURMOUNT-1 sponsor results.

An estimand specifies the effect the trial aims to estimate, including how events such as treatment discontinuation are handled. The efficacy analysis asks about the effect under continued treatment conditions defined by the trial; the treatment-regimen analysis includes the consequences of discontinuation within its defined strategy.

Neither is automatically the “real” result while the other is false. They answer different questions. The error is switching between them without telling the reader—or pairing one drug's efficacy result with another drug's treatment-regimen result to make the gap look larger.

For a fair reading of any new headline, ask four questions: which population, which dose group, which timepoint, and which analysis? If one answer is missing, the percentage is incomplete.

The prominent TRIUMPH-1 and SURMOUNT-1 figures above come from studies without diabetes. They should not be presented as the expected effect in someone with type 2 diabetes.

Two placebo-controlled studies address this population directly:

Sources: Bellido et al., 2026, TRIUMPH-2, Garvey et al., 2023, SURMOUNT-2. Both are treatment-regimen estimates in the randomised population. SURMOUNT-2 explicitly assessed effects regardless of stopping treatment or starting rescue glucose-lowering therapy; TRIUMPH-2 used its specified multiple-imputation strategy for missing data. These are research target groups, not prescribing instructions.

These rows supply diabetes-specific context for both compounds, but remain an indirect comparison. Baseline BMI, glucose control, medication context, duration and analysis details differ. The numbers do not establish which would produce more weight loss in the same person.

The same discipline applies to knee osteoarthritis, sleep apnoea and cardiovascular outcomes. A trial can measure improvement in one condition without establishing every possible long-term health benefit. Weight reduction alone cannot stand in for all of those endpoints.

Both programmes reported gastrointestinal symptoms. The key questions are frequency, intensity, persistence and whether people stopped treatment. Those are related, but distinct.

The available stopping-treatment findings are concrete, but come from separate studies without diabetes:

Sources: TRIUMPH-1 original ADA presentation, SURMOUNT-1 primary paper. Each denominator belongs to that study's reporting population; the source categories and exposure periods differ. This is an indirect comparison of reported AE discontinuations, not a head-to-head estimate of tolerability or a count of confirmed drug injuries.

Retatrutide's original TRIUMPH-1 congress safety tables show nausea, diarrhoea, constipation and vomiting, alongside fatigue and dysesthesia. Dysesthesia refers to abnormal or unpleasant sensation, including skin burning; it is not simply another name for an injection-site reaction. Original ADA presentation.

Participant selection, reporting methods, exposure time, escalation schedules and background event rates can all affect the percentages.

“Serious” also does not mean “severe”. Serious adverse events use outcome-based reporting criteria, while severe describes intensity. A person stopping a study because nausea is unacceptable does not necessarily have a serious event. Any useful safety comparison needs those categories kept separate.

The direct TRIUMPH-5 study should make the comparison more informative if completed and reported. Until then, it is premature to claim an overall tolerability winner from separate publications.

Neither receptor count nor a larger change on the scale answers that question. Weight includes fat and non-fat tissue, and lean mass is not identical to contractile muscle or strength.

A 2025 retatrutide DXA substudy by Coskun and colleagues measured body composition in people with type 2 diabetes. It found fat-mass reduction and reported a proportion of lean-mass loss similar to other obesity treatments. The analysis used on-treatment observations, with 103 participants completing both baseline and week-36 scans out of 189 enrolled in the substudy. Primary record.

That was not a randomised muscle-preservation comparison against tirzepatide. Its findings do not prove retatrutide builds muscle, loses only fat or protects strength better. A convincing comparison would need relevant composition measurements and functional outcomes in comparable participants.

This matters when assessing a dramatic before-and-after claim. A scale reading can confirm a change in total mass. It cannot tell us the complete composition of that change, let alone demonstrate improved performance.

Mounjaro contains tirzepatide. Australia's TGA registered its chronic weight-management indication in September 2024, alongside reduced-calorie eating and increased physical activity, for adults meeting the specified BMI and comorbidity criteria. The Australian assessment also documents its diabetes indication. TGA registration, Australian assessment.

US material commonly discusses Zepbound for obesity and Mounjaro for diabetes. Both contain tirzepatide, but the brand-specific US indications should not be imported into Australian copy. FDA explanation.

Registration does not mean a medicine suits everyone or has no material precautions. Australia's TGA has also updated tirzepatide advice concerning oral contraception when treatment starts or doses increase. Anyone considering prescribed treatment should use the current Australian product information with their clinician. TGA safety update.

TRIUMPH-5, NCT06662383, directly compares retatrutide with tirzepatide in adults with obesity. On the registry checked for this article, it was active but not recruiting, with no results posted. Its July 2026 update estimated primary completion in November 2026. An estimated completion date is a planning field, not a guarantee of a publication date.

Direct randomisation addresses a problem the separate trials cannot: participants enter the same study and are assigned to the competing treatments. The eventual result will still need assessment of its population, treatment exposure, missing data and selected endpoints. A head-to-head label does not remove those questions, but it makes a comparative effect much more interpretable.

Until a result is available, claims that retatrutide has already “won” against Mounjaro go beyond the evidence inspected here.

Published trials investigate controlled formulations under clinical protocols. A vial marketed with the same compound name does not inherit those results. Nominal content and a supplier report cannot establish equivalence to Mounjaro or the retatrutide formulation used in Lilly's studies.

For quantity and format questions, the retatrutide vial-size guide has a separate job. For document interpretation, read how to read a laboratory report. Neither is a substitute for an approved medicine or a personal treatment assessment.

Is retatrutide stronger than Mounjaro?

“Stronger” needs a measured outcome. Retatrutide has produced numerically larger weight changes in selected separate trials, but the direct comparison has no posted results at this review. Milligrams and receptor counts cannot decide the question.

Are tirzepatide and Mounjaro the same thing?

Tirzepatide is the active ingredient; Mounjaro is a branded pharmaceutical formulation containing it. A product labelled tirzepatide is not automatically the registered Mounjaro medicine.

Can one be swapped for the other at an equivalent dose?

The research presented here establishes no milligram-for-milligram conversion. Study target doses are not a switching guide, and retatrutide remains investigational.

Which result should I use when comparing a headline?

Use the analysis definition attached to the result and keep population and timepoint visible. A treatment-regimen estimate and an efficacy estimate answer different questions; neither should lose its label when quoted.